Veristrat can be used to identify a group of patients with worse progression-free (PFS) when treated with Femera alone, independent of Her2 status.
A retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual San Antonio Breast Cancer Symposium SABCS.